Plain-English translation of NCT06702124 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called rotigotine—given as a patch you wear on your skin—to see if it can help improve memory and thinking in people with mild to moderate Alzheimer's disease. You would receive the medication along with rivastigmine, a drug you may already be taking. Researchers will measure how the medication affects your memory, thinking, and overall brain function over 24 weeks.
Current treatments for Alzheimer's help slow some symptoms, but many people still experience worsening memory and thinking problems. This trial explores whether adding this medication to existing treatment might offer better help for people in the early-to-middle stages of the disease.
You likely qualify if…
You likely don't qualify if…
You will visit the research clinic multiple times over 6 months for memory and thinking tests, physical exams, and brain imaging. You'll wear a rotigotine patch (or placebo patch if randomly assigned to the control group) every day and continue your current rivastigmine medication. During the study, researchers will check your progress at weeks 6, 12, and 24, and your caregiver will receive phone check-ins between visits to watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Italy